- Lantheus (NASDAQ:LNTH) and its associates entered agreement with Radiopharm Theranostics – a developer of diagnostic and therapeutic radiopharmaceutical merchandise.
- Lantheus (LNTH) has agreed to make an preliminary fairness funding of A$7.5M ($4.99M) and could have an choice to speculate an additional A$7.5M ($5M) inside 6 months on the identical phrases.
- Moreover, Radiopharm has agreed to switch two of its early preclinical belongings to Lantheus (LNTH) for A$3M ($2M) pursuant to a separate switch and improvement settlement.
- The provide worth for the shares of A$0.05 represents a 47% premium to the final closing worth of $0.034 on 19 June 2024.
- The online proceeds of Lantheus’ funding might be utilized by the corporate for drug manufacturing, scientific trials and common working capital.